-transparent.png){kind=logo}
Twelve healthy male subjects received single oral doses of etretinate, ranging from 25 to 100 mg (1 to 4 x 25-mg capsules) in an open-label, four-way randomized crossover design. Plasma concentrations of etretinate and two active metabolites were determined by a specific high-performance liquid chromatographic (HPLC) method. Analysis of variance and orthogonal contrasts were used to assess dose proportionality. Mean (+/- %CV) maximum concentrations after 25- to 100-mg doses were 133 (50), 195 (33), 261 (53), and 446 (65) ng/ml, whereas AUC0-12 values were 581 (46), 1090 (39), 1500 (52), and 2440 (63) ng.hr/ml, respectively. The test for proportionality indicated that Cmax and AUC0-12 increased proportionally with an increase in dose (P greater than 0.05).
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
January 1993,
European journal of clinical pharmacology,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
November 2002,
Evidence-based mental health,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
January 1983,
Research communications in chemical pathology and pharmacology,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
January 1989,
Therapie,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
August 2016,
Epilepsia,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
January 1982,
Biopharmaceutics & drug disposition,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
March 1998,
Headache,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
October 2022,
ANZ journal of surgery,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
September 2016,
ANZ journal of surgery,
R J Wills, and
L C Rodriguez, and
A H Lin, and
C Puccini, and
W A Colburn
April 2018,
ANZ journal of surgery,
